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Abstract
Background: Recent evidence from in vitro and in vivo studies has demonstrated that aberrant reactivation of the Sonic
Hedgehog (SHH) signaling pathway regulates genes that promote cellular proliferation in various human cancer stem cells
(CSCs). Therefore, the chemotherapeutic agents that inhibit activation of Gli transcription factors have emerged as
promising novel therapeutic drugs for pancreatic cancer. GDC-0449 (Vismodegib), orally administrable molecule belonging
to the 2-arylpyridine class, inhibits SHH signaling pathway by blocking the activities of Smoothened. The objectives of this
study were to examine the molecular mechanisms by which GDC-0449 regulates human pancreatic CSC characteristics in
vitro.
Methodology/Principal Findings: GDC-0499 inhibited cell viability and induced apoptosis in three pancreatic cancer cell
lines and pancreatic CSCs. This inhibitor also suppressed cell viability, Gli-DNA binding and transcriptional activities, and
induced apoptosis through caspase-3 activation and PARP cleavage in pancreatic CSCs. GDC-0449-induced apoptosis in
CSCs showed increased Fas expression and decreased expression of PDGFRa. Furthermore, Bcl-2 was down-regulated
whereas TRAIL-R1/DR4 and TRAIL-R2/DR5 expression was increased following the treatment of CSCs with GDC-0449.
Suppression of both Gli1 plus Gli2 by shRNA mimicked the changes in cell viability, spheroid formation, apoptosis and gene
expression observed in GDC-0449-treated pancreatic CSCs. Thus, activated Gli genes repress DRs and Fas expressions, up-
regulate the expressions of Bcl-2 and PDGFRa and facilitate cell survival.
Conclusions/Significance: These data suggest that GDC-0499 can be used for the management of pancreatic cancer by
targeting pancreatic CSCs.
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Introduction
Pancreatic cancer (PC) is a highly lethal malignancy character-
ized by late diagnosis and treatment resistance. PC is the fourth
leading cause of cancer in the United States with a 5-year survival
less than 5%. Surgical resection is the only potentially curative
therapeutic option for PC; however, due to the lack of early
symptoms, the vast majority of patients present with metastatic
disease, rendering their malignancy inoperable [1,2]. The current
standard-of-care therapy, gemcitabine, extends patient survival by
only a few weeks [3]. The identification of new molecular targets
for PC to overcome the dismal prognosis is therefore necessary.
Recurrent genetic alterations in defined genes in association with
perturbations of developmental cell signaling pathways have been
associated with PC development and progression. Recent evidence
from in vitro and in vivo studies suggests that the Sonic Hedgehog
(SHH) signaling pathway [4] is aberrantly reactivated and
recognized as one of the mediators in the majority of PCs;
therefore, SHH blockade has the potential to prevent disease
progression and metastatic spread [5].
SHH signaling is initiated by the binding of short-acting
polypeptide ligand namely Shh (Sonic Hedgehog, Indian Hedge-
hog or Desert Hedgehog) to its receptor, Patched which thereby,
diminishes the inhibitory effects of Patched on Smoothened [6].
Smoothened is then localized into the primary cilium of the cell,
an organelle playing a critical role in SHH signaling [7]. There,
Smoothened activates an intracellular cascade that results in
activation and nuclear translocation of Gli family transcription
factor Gli2 [8]. Gli2 translocates into the nucleus and induces the
transcription of SHH target genes, such as Gli1, a reliable marker
of SHH signaling [8,9]. Gli2 is a critical component of SHH
signaling and its inactivation leads to an inhibition of SHH
signaling. These Gli transcription factors turn on genes in the
nucleus that promote cellular proliferation, cellular survival,
stemness, and cell fate determination in a variety of organs
[5,10]. SHH pathway is a morphogen required for proper pattern
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pathway is responsible for several human cancers [8,10,11].
Recent evidence indicates that SHH signaling pathway at the level
of Gli genes has a critical role in normal pancreas development
and there is mounting evidence that dysregulated SHH signaling
plays some role in pancreatic cancer [12]. Furthermore, several
reports indicate that human pancreatic cancers over express Gli
genes [13,14].
Transcription factors of the Gli family have dual functions such
as activator and repressor that are defined only partially and can
respond to combinatorial and cooperative Gli activity. The Gli
family plays critical roles in the mediation and interpretation of
SHH signals [15]. SHH-driven cancers arise from a variety of
mutations that affect different components, including the key
transcriptional effector Gli proteins, leads to a variety of human
malignancies including medulloblastoma, rhabdomyosarcoma,
melanoma, basal cell carcinoma, and breast, lung, liver, stomach,
prostate, and pancreatic cancers [16,17,18,19,20]. Constitutively,
SHH-Gli signaling is active in basal cell carcinomas, medulloblas-
tomas and cancers of esophagus, due to mutation in Patched or
Smoothened [21,22]. Melanomas and carcinomas of the prostate
have further shown a SHH-Gli signaling axis [23]. In gastroin-
testinal cancers, SHH signaling activation occurs through
transcriptional up regulation of the SHH ligand [24]. It has
recently been suggested that SHH signaling progresses during
colon carcinogenesis [25,26] and in metastatic disease [27]
whereas in normal colonic tissue, SHH signaling is involved in
differentiation [28]. Recently, genes have been profiled that are
regulated downstream of Gli1 and Gli2 that are involved in cell
proliferation and cell cycle [29,30], and cell survival (PDGFRa
and Bcl-2) [22]. Gli2 is also expressed in many basal cell
carcinomas [31], suggesting that these genes might also be
involved in the development of PC, which could be consistent
with its partial action as mediator of SHH signals [32]. However,
the roles of Gli genes (Gli1 and Gli2) in SHH-driven cellular
survival and cell death responses remain ill-defined, and
specifically, their role in cellular proliferation and survival of
pancreatic CSCs is unknown and the downstream target genes
involved in determination of cell fate.
Much attention has been recently focused on the role of cancer
stem cells (CSCs)/cancer initiating cells (CICs) in the initiation and
progression of solid malignancies. CSCs may be responsible for
tumor onset, self-renewal/maintenance, mutation accumulation,
and metastasis due to their ability to express anti-apoptotic and
drug resistant proteins, thus sustaining tumor growth [33,34]. The
SHH signaling pathway is a key regulator of physiological cell
processes which include proliferation, differentiation, and apopto-
sis [35]. Recent studies indicate that SHH signaling system plays a
key role also in CSC biology including in the regulation of CSCs
self-renewal, differentiation; and tumorigenic potential, suggesting
SHH signaling could be a promising therapeutic target in PCs
[14]. Activating SHH signaling may abrogate the resistance of
CSCs to chemotherapy and could lead to the development of
novel therapeutic approaches for the treatment of PCs.
To identify downstream targets of the Gli genes that regulate
cellular proliferation and survival in pancreatic cancer stem cells
(CSCs), we employed an inhibitor of SHH signaling, GDC-0449
(Smoothened inhibitor), which has been identified in a cell-based
small molecule screen for inhibitors of Gli family-mediated
transcription [36]. GDC-0449 acts as a potent inhibitor of
Smoothened and shows a high degree of selectivity for SHH-Gli
signaling [36]. In human pancreatic CSCs, we showed the
inhibition of the SHH signaling pathway by targeting the Gli
transcription factors. GDC-0449 induced significant cell death in
three pancreatic cancer cell lines (AsPC-1, PANC-1 and MIA
PaCa-2) and pancreatic CSCs. In further detailed analyses of
pancreatic CSCs, GDC-0449 decreased SHH signaling compo-
nents (Gli1, Gli2, Patched-1, Patched-2, SHH and Smoothened)
expression, Gli-DNA binding and Gli-luciferase reporter activities.
In addition, knockdown of both Gli1 and Gli2 expressions using
shRNA conferred resistance to GDC-0499-induced cytotoxicity.
Furthermore, GDC-0449 decreased the expression of PDGFRa
concomitant with elevated levels of Fas, increased the expression
of TRAIL-R1/DR4 and TRAIL-R2/DR5, decreased Bcl-2
expression, and induced caspase-3 activity and PARP cleavage.
GDC-0449-induced changes in gene expression and apoptosis
were blocked by Gli1 plus Gli2 shRNA, thus pointing a role of Gli
for cellular proliferation and survival in human pancreatic CSCs.
These data suggest that GDC-0449 suppresses pancreatic CSCs
proliferation and survival by inhibiting SHH signaling pathway at
the level of Gli genes.
Results
SHH pathway signaling components are expressed in
human pancreatic cancer cell lines and pancreatic CSCs
We first measured the expression of various components of
SHH pathway in human pancreatic cancer AsPC-1, PANC-1, and
MIA-PaCa-2 cell lines and pancreatic CSCs by RT-PCR (Fig. 1).
The data demonstrate that the components of SHH signaling
pathway, including the ligand (Shh), the signaling molecules
(Patched-1, Patched-2 and Smoothened) and effectors (Gli1, and
Gli2) are expressed in human pancreatic cancer cell lines and
pancreatic CSCs. These data suggest that SHH pathway is intact
in pancreatic cancer cell lines and CSCs, and supports the concept
that the binding of the Shh ligand to the Patched receptor
diminishes its inhibitory effects on Smoothened, allowing signal
transduction that will result in activation and nuclear translocation
of Gli family transcription factors [13,37].
GDC-0449 reduces cell viability and induces apoptosis in
human pancreatic cancer cell lines and pancreatic CSCs
Previous clinical studies have suggested that GDC-0449 is a
small molecule inhibitor of Smoothened. We first sought to
examine the effects of GDC-0499 on cell viability and apoptosis in
the panel of three human pancreatic cancer cell lines and
pancreatic CSCs. Inhibition of cell survival and induction of
apoptosis was observed within 24 h following exposure to this drug
(data not shown), but was maximally noticed at 72 h (Figs. 2 and
3). In all the cell lines, GDC-0449 induced apoptosis is a dose-
dependent manner reaching up to 65%. By comparison, GDC-
0449 was less effective in inducing apoptosis in CSCs (Fig. 3). For
further mechanistic studies we have used pancreatic CSCs.
GDC-0449 regulates downstream targets of SHH
pathway, inhibits Gli-DNA interaction, Gli transcriptional
activity and decreases Gli nuclear translocation in
pancreatic CSCs
We next examined the effect of GDC-0449 on the expression of
Fas, DR4/TRAIL-R1, DR5/TRAIL-R2, PARP, Bcl-2, caspase-
3, and PDGFRa by the western blot analysis (Fig. 4). GDC-0449
induced the expression of Fas, DR4, and DR5 and inhibited the
expression of Bcl-2 and PDGFRa in pancreatic CSCs. In addition,
GDC-0449 induced the cleavage of caspase-3 and PARP in
pancreatic CSCs, correlating with the extent of cell survival and
apoptosis.
Inhibition of Pancreatic CSCs by GDC-0449
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pathway by measuring the expression of SHH receptors (Patched-
1, Patched-2 and Smoothened) and effectors (Gli1 and Gli2) by
qRT-PCR (Fig. 5A). GDC-0449 inhibited the expression of
smoothened, Patched-1, and Patched-2. Similarly, GDC-0449
inhibited the expression of transcription factor Gli1 and Gli2.
These data suggest that GDC-0449 can regulate CSC character-
istics by inhibiting various components of SHH pathway.
Since Gli mediates the effects of Shh, we next examined the Gli-
DNA interaction by electrophoretic mobility shift assay (EMSA) in
human pancreatic CSCs. Treatment of CSCs with GDC-0449
resulted in decreased Gli-DNA binding activity in a dose-
dependent manner (Fig. 5B).
We next examined the effect of GDC-0449 on Gli transcrip-
tional activity (Fig. 5C). Exposure of CSCs with GDC-0449 for
36 h resulted in inhibition of Gli-dependent luciferase reporter
activity in a dose-dependent manner. GDC-0449 inhibited the
expression of Patched-1 and Patched-2 because they are
downstream targets of Gli. We next employed immunofluores-
cence technique to examine the effects of GDC-0449 on nuclear
expression of Gli (Fig. 5D). Pancreatic CSCs were treated with
GDC-0449, and the nuclear expression of Gli1 and Gli2 was
observed. GDC-0449 inhibited the nuclear expression of Gli1 and
Gli2. Overall, these data suggest that GDC-0449 can inhibit Gli
DNA binding and transcriptional activity.
Human pancreatic CSCs require active Gli function for
sustained expression of genes involved in the cell
survival and proliferation
In order to examine the effects of Gli1 and Gli2 on cell
proliferation, apoptosis and down-stream targets, we inhibited the
expression of Gli1 and Gli2 transcription factors by shRNA. As
shown in Fig. 6A, lentiviral mediated expression of Gli1 and Gli2
shRNA inhibited the expression of Gli1 and Gli2 proteins in
pancreatic CSCs. If GDC-0449 inhibits cell viability and induces
apoptosis by inhibiting Gli transcription factors, the inhibition of
Gli1 and Gli2 should block the anti-proliferative and pro-apoptotic
effects of GDC-0449. To confirm the Gli-dependent anti-
proliferative and pro-apoptotic effects GDC-0449, we used
pancreatic CSCs expressing Gli1 + Gli2 shRNA (Fig. 6B).
GDC-0449 inhibited cell viability and induced apoptosis in
CSCs/scrambled cells. Inhibition of Gli1 and Gli2 alone by
Figure 1. Expressing components of Sonic Hedgehog (SHH) signaling pathway in human pancreatic cancer cell lines and pancreatic
cancer stem cells (CSCs). Pancreatic cancer cells (AsPC-1, PANC-1 and MIA PaCa-2) and pancreatic CSCs were grown for 48 h. Total RNA was
isolated and expression of Shh, Patched-1, Patched-2, Smoothened, Gli-1 and Gli-2 was measured by qRT-PCR. HK-GAPD was used as endogenous
normalization control. All assays were performed in triplicate and were calculated on the basis of DDCt method. The n-fold change in mRNAs
expression was determined according to the method of 2
-DDCT with GAPDH employed as the endogenous control.
doi:10.1371/journal.pone.0027306.g001
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on CSC’s viability (data not shown). By comparison, inhibition of
Gli1 plus Gli2 together by shRNA suppressed the effects of GDC-
0449 on cell viability and apoptosis in CSCs. These data suggest
that both Gli1 and Gli2 genes are required for anti-proliferative
and pro-apoptotic effects of GDC-0449.
We next examined the effects of inhibiting Gli expression on
downstream target of SHH pathway by Western blot analysis
(Fig. 6C). GDC-0449 (10 mM) induced the expression of Fas, DR4
and DR5, cleaved PARP, and inhibited the expression of Bcl-2 and
PDGFRa in CSC/scrambled cells. It is interesting to note that the
expression of PDGFRa was decreased following GDC-0449
treatment with concomitant increase in Fas. By comparison, GDC-
0449 had no significant effects on expression of these downstream
targets of SHH signaling pathway in CSCs/Gli1 + Gli2 shRNA cells.
We next examined the effect of GDC-0449 on primary and
secondary spheroid formation (Fig. 6D). GDC-0449 inhibited the
formation of primary and secondary spheroids in CSC/scrambled
cells. By comparison, transduction of Gli1 plus Gli2 shRNA in
CSCs suppressed the inhibitory effects of GDC-0449 on primary
and secondary spheroid formation. These data suggest that GDC-
0449 can inhibit pancreatic CSC characteristics.
Discussion
Our study demonstrates, for the first time, that Smoothened-
dependent therapeutic agent GDC-0449 regulates cellular survival
in human pancreatic CSCs. Specifically, GDC-0449 inhibited cell
viability and induced apoptosis in three pancreatic cancer cell lines
and pancreatic CSCs. In pancreatic CSCs, GDC-0449 also
suppressed the cell viability, Gli-DNA binding and Gli-transcrip-
tional activities, induced apoptosis through caspase-3 activation
and PARP cleavage. Analysis of the molecular mechanisms of
GDC-0449-induced cell death in CSCs showed increased Fas
expression and decreased expression of PDGFRa, which also
regulates Fas. Furthermore, Bcl-2 was down-regulated whereas
DR4 and DR5 expressions were increased following the treatment
of GDC-0449. Suppression of both Gli1 plus Gli2 by shRNA
mimicked the changes in cell viability, spheroid formation,
apoptosis and death-related gene expression observed in GDC-
0449-treated pancreatic CSCs. Thus, activated Gli genes repress
DRs and Fas expressions while up-regulating Bcl-2 and PDGFRa
expressions to inhibit Fas. Our results highlight the critical role of
SHH signaling in human pancreatic CSCs and the possibility of
targeting Gli1 and Gli2 activator functions using GDC-0449 in
pancreatic cancer stem cells.
SHH signaling events have been implicated in tumor cell
proliferation and survival as well as is the molecular hallmark of
different human tumor entities that include esophageal squamous
cell carcinoma, basal cell carcinoma [38], subsets of medulloblas-
toma [39], prostate cancer [40], colon cancer [41], brain tumors
[42], rhabdomyosarcoma [43], and breast cancer [44]. Multiple
lines of evidence support the idea that SHH signaling is a
Figure 2. Inhibition of SHH signaling suppressed cell viability in human pancreatic cancer cell lines and pancreatic CSCs by GDC-
0449. Cells were treated with GDC-0449 (0, 1, 5 and 10 mM) for 48 and 72 h. At the end of incubation period, cell viability was measured by XTT in (A)
AsPC-1, (B) MIA PaCa-2, (C) PANC-1, and (D) Pancreatic CSCs. Data represent mean 6 SD. @ or # significantly different from respective control
(P,0.05).
doi:10.1371/journal.pone.0027306.g002
Inhibition of Pancreatic CSCs by GDC-0449
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that blocking active SHH signaling with the therapeutic inhibitor
molecules such as GANT-61 (targeting effectors Gli1 and Gli2)
and cyclopamine (targeting SHH receptor Smoothened) induced
cell death [45]. We have shown that human pancreatic cancer cell
lines and CSCs consistently express various components of SHH
pathway including effectors (Gli1 and Gli2), and receptors
(Patched-1, Patched-2, and Smoothened), and most importantly
the ligand: SHH, suggesting, SHH pathway is one of the ‘‘core’’
signaling pathway or an autocrine mode of SHH signaling in these
cells. Activation of the SHH signaling cascade consistently induces
Gli family transcription factors (Gli1 and Gli2), hence both Gli
genes mRNA [46], expressed in pancreatic cancer cell lines and
CSCs, stating potential involvement of SHH signaling in human
pancreatic carcinogenesis.
Aberrant activation of SHH signaling is implicated in many
human cancers. To identify new therapeutic targets, inhibition of
SHH signaling has been attempted in multiple human cancers
[11,41,45]. Recently, Gli and Smo antagonists have been used to
abrogate SHH signaling in human cancers (40). Natural and
synthetic Smoothened antagonists such as cyclopamine [24] and
IPI-926 [11], respectively have inhibited proliferation, survival and
have anti-tumor functions, resulting in abrogation of SHH
signaling. However, during the clinical trials various levels of
resistance have been observed. Pharmacologic agents including
cyclopamine (11), GDC-0499 and GANT-61 [41] have inhibited
survival and antitumor functions in preclinical models of human
cancers. Gli genes are potential members of SHH pathway, which
act as downstream mediators of SHH signaling and they have
regulatory effects on cell cycle and apoptosis. Hence, one potential
druggable target lies in Gli family transcription factors, which are
the final mediators of transcriptional regulation in the SHH
signaling pathway. In the present study, exposure to GDC-0449
induces significant cytotoxicity and apoptosis in human pancreatic
cancer cells and CSCs.
GDC-0449 treatment effectively decreased Gli-DNA binding
and Gli-transcriptional activity in human pancreatic CSCs. These
results are suggesting that GDC-0449 may induce posttranscrip-
tional alterations of Gli gene, which might point towards, an
increase in phosphorylation that either prevent DNA binding or
destabilize the Gli-DNA complex. Post-translational modifications
of Gli gene is an important mechanism that regulates the ability of
different transcription factors to inhibit distinct gene sets, involved
in regulation of cell death inhibition [41], consistent with previous
observations in pancreatic cancer cells engineered to express Gli1
[13]. Of particular interest, Smoothened-dependent GDC-0449
treatment of pancreatic CSCs markedly inhibited expressions of
SHH receptors (Patched-1, Patched-2 and Smoothened) and
effectors (Gli1 and Gli2), thereby showing potential for therapeutic
application for treatment of pancreatic cancer. It was previously
reported that GDC-0449 was identified as inhibitor of Gli1
transcriptional activity, and also abrogated Gli2-mediated tran-
Figure 3. Induction of apoptosis by GDC-0449 in pancreatic cancer cell lines and pancreatic CSCs. The cells were treated with GDC-0449
(0, 1, 5 and 10 mM) for 48 and 72 h. At the end of incubation period, cells were harvested and apoptosis was measured. Data represent mean 6 SD. @
or # significantly different from respective control (P,0.05).
doi:10.1371/journal.pone.0027306.g003
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Gli2 expression preceded that of Gli1 in pancreatic CSCs.
Further, studies in mice have revealed that Gli2 is primary
mediators of SHH signaling and is known to transcriptionally
regulate Gli1 expression [25]. Because the SHH signaling pathway
is already activated in human pancreatic CSCs, studies using
shRNA knockdown of Gli1 and Gli2 alone and simultaneously
were conducted. GDC-0449 significantly inhibited cell viability
and induced apoptosis in shRNA Gli1 and Gli2 alone (data not
shown). Interestingly, significant protection from GDC-0449-
induced cytotoxicity and apoptosis was recorded in shRNA
knockdown of both Gli1 and Gli2. These data further support
the idea that GDC-0449 may have Gli-dependent and -
independent mode of action (Fig. 7) and further show the
importance of functional Gli genes in maintaining cellular survival
in human pancreatic CSCs.
To assess antiproliferative effect of GDC-0449 in more detail,
we next correlated the expression of cell cycle and apoptosis-
related genes with SHH signaling in pancreatic CSCs. In several
stem cells and cancer cells, SHH acts as a survival factor [9,47].
SHH has been reported to control the proliferation of several cell
types through various molecular mechanisms such as increase in
PDGFRa and Bcl-2 expressions, decrease in DRs and Fas
expressions, and inhibition of PARP cleavage and caspase-3
activation in colon cancer cell lines overexpressing Gli genes [41]
or, an overexpression of dominant-negative FADD in cells
expressing SHH or a constitutively active Smoothened [41]. In
our study, GDC-0449 induced a marked increase in the expression
of Fas and both DRs (TRAIL-R1/DR4 and TRAIL-R1/DR5),
suggesting the potential involvement of these DRs in drug-induced
apoptosis. Recent reports indicated the absence of Gli binding sites
in the promoter region of DR4 and DR5. The regulation of DR
expression by the Gli is currently unknown and may be via an
indirect mechanism. However, GDC-0449 induced up regulation
of both DRs in pancreatic CSCs, suggesting transcriptional
regulation of DRs by a currently unknown mechanism. We also
determined the contributions of apoptotic cell death pathways
(mitochondria-mediated intrinsic and death receptor signaling-
mediated extrinsic), based on the known regulation of PDGFRa
upstream of Fas [2,48], and of Bcl-2, which may be a direct
transcriptional target of both Gli1 and Gli2, a key anti-apoptotic
protein in SHH-dependent cell survival [49]. We have shown that
GDC-0449 treatment reduces pro-survival protein Bcl-2 expres-
sion in pancreatic CSCs. Thus, our data demonstrate that
activation of SHH pathway can regulate genes involved in both
cell-extrinsic and cell-intrinsic pathways of apoptosis.
Together, this study reveals that endogenous SHH signaling
controls the self-renewal capacity of human pancreatic CSCs by
targeting down-stream targets of Gli. In conclusion, GDC-0449
can be used for the treatment of human pancreatic cancer because
it can target pancreatic cancer CSCs.
Methods
Antibodies and reagents
Antibodies against SHH, Smoothened, Fas, TRAIL-R1/DR4,
TRAIL-R2/DR5, and b-actin were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA). Antibodies against Gli1,
Gli2, Patched-1, Patched-2, PDGFRa and caspase-3 were
obtained from Cell Signaling Technology (Danvers, MA).
Enhanced chemiluminescence (ECL) Western blot detection
reagents were from Amersham Life Sciences Inc. (Arlington
Heights, IL). GDC-0449 (Vismodegib; C19H14Cl2N2O3S) was
purchased from Tocris (Ellisville, MO). All other chemicals used
were of analytical grade and were purchased from Fisher Scientific
(Suwanee, GA) and Sigma-Aldrich (St. Louis, MO).
Cell culture
Pancreatic cancer cell lines (AsPC-1, PANC-1 and MIA PaCa-
2) were obtained from American Type Culture Collection
(Manassas, VA) and cultured in RPMI 1640 supplemented with
10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic at
37uC in a humidified atmosphere of 95% air and 5% CO2.
Human pancreatic CSCs (CD133
+/CD44
+/CD24
+/ESA
+) were
obtained from Celprogen Inc. (San Pedro, CA). They were
isolated from primary tumors and have been described previously
[33]. The CSCs were cultured in DMEM supplemented with 1%
N2 Supplement (Invitrogen), 2% B27 Supplement (Invitrogen),
20 ng/ml human platelet growth factor (Sigma-Aldrich), 100 ng/
ml epidermal growth factor (Invitrogen) and 1% antibiotic-
antimycotic (Invitrogen) at 37uC in a humidified atmosphere of
95% air and 5% CO2. Pancreatic CSCs were routinely verified by
morphology and growth characteristics.
Lentiviral particle production and Gli1 shRNA and Gli2
shRNA transduction
Gli1 shRNA (59-GCCTGAATCTGTGTATGAA-39;5 9-
GTTTGAATCTGAATGCTAT-39;5 9- AGCTAGAGTCCA-
GAGGTTC-39;5 9- CCGGAGTGCAGTCAAGTTG-39 and 59-
GGCTGGACCAGCTACATCA-39) and Gli2 shRNA (59-
CCGAGAAGCAAGAAGCCAA-39;5 9- CACAGCATGCTC-
TACTACT-39;5 9- TCGCTAGTGGCCTACATCA-39;5 9-TC-
CGAGAAGCAAGAAGCCA-39 and 59- CCAGACGACGT-
GGTGCAGT-39) were obtained from Open Biosystems, Hunts-
Figure 4. GDC-0449 differentially regulates genes involved in
the balance between cell death and cell survival. Pancreatic CSCs
were treated with GDC-0449 (0, 1, 5 and 10 mM) for 48 h. The
expression of Fas, DR4/TRAIL-R1, DR5/TRAIL-R2, PARP cleavage, Bcl-2,
and Caspase-3 by the Western blot analysis. b-Actin was used as a
loading control.
doi:10.1371/journal.pone.0027306.g004
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produced by triple transfection of HEK 293T cells. Packaging
293T cells were plated in 10-cm plates at a cell density of 5610
6 a
day prior to transfection in DMEM containing 10% heat-
inactivated fetal bovine serum without antibiotics. Transfection
of packaging cells and infection of pancreatic CSCs were carried
out using standard protocols [50] with some modifications. In
brief, 293T cells were transfected with 4 mg of plasmid and 4 mgo f
lentiviral vector using lipid transfection (Lipofectamine/Plus
reagent, Invitrogen) according to the manufacturer’s protocol.
Viral supernatants were collected and concentrated by adding
PEG-it virus precipitation solution (SBI System Biosciences) to
produce virus stocks with titers of 1610
8 to 1610
9 infectious
units/ml. Viral supernatant was collected for three days by
ultracentrifugation and concentrated 100-fold. Titers were deter-
mined on HEK293T cells. Pancreatic CSCs were transduced with
lentivirus expressing scrambled shRNA (control), Gli1 shRNA, or
Gli2 shRNA. Pancreatic CSCs simultaneously expressing both
Gli1 plus Gli2 shRNA were also generated. Following transduc-
tion, the CSCs were washed 3 times with Difco’s 1X PBS and
allowed to grow for 3 passages before screening for gene
expression. Once decreased expression of the targeted gene was
confirmed, the cells were used for experiments. Stable expression
of Gli1 ShRNA or Gli2 shRNA was ensured by culturing cells in
the presence of a selection antibiotic puromycin (5.0 mg/ml),
whereas induction of both Gli1 shRNA and Gli2 shRNA was
Figure 5. GDC-0449 downregulates the expression of various components of SHH signaling pathway in pancreatic CSCs. (A),
Pancreatic CSCs were treated with GDC-0449 (10 mM) for 36 h. At the end of incubation period, RNA was extracted and the expression of Gli1, Gli2,
Patched-1, Patched-2, Smoothened and Shh was measured by qRT-PCR. Data represent the mean 6 SD. @ significantly different from respective
control (P,0.05). (B), Pancreatic CSCs were treated with and GDC-0449 (0, 1, 5 and 10 mM) for 48 h. Nuclear extracts were prepared and the gelshift
experiment was performed. Probe only, control (without GDC-0449), and GDC-0449 treated samples (1, 5 and 10 mM), respectively. The data are
representative of three experiments. (C), Gli-dependent luciferase activity is reduced by GDC-0499. Pancreatic CSCs were transduced with lentiviral
construct expressing Gli-dependent luciferase reporter, and treated with GDC-0449 (0, 5 and 10 mM) for 48 h. Lysates were prepared, and luciferase
activity was measured. Normalized luciferase activity is presented as mean 6 SD. @ or # significantly different from respective control (P, 0.05). (D),
GDC-0449 inhibits expression of Gli1 and Gli2 in human pancreatic CSCs. The cells were seeded on fibronectin-coated coverslips and treated with
GDC-0449 (10 mM) for 48 h. Subsequently, cells were fixed with 4% paraformaldehyde, blocked in 10% normal goat serum and stained with Gli1 and
Gli2 primary antibodies (1:100) for 16 h at 4uC and washed with PBS. Afterwards, cells were incubated with fluorescently labeled secondary antibody
(1:200) along with DAPI (1 mg/ml) for 1 h at room temperature and cells were mounted and visualized under a fluorescent microscope. For better
visuality, the color of DAPI was changed from blue to red.
doi:10.1371/journal.pone.0027306.g005
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transduced CSCs were washed three times with PBS (without
Ca
++ or Mg
++) and used for experiments.
Cell viability and apoptosis assays
Cells (1.5610
4) were incubated with 0-10 mM of GDC-0449 in
250 ml of culture medium in 96-well plate for 48 and 72 h before
cell viability determination. Cell viability was determined by the
XTT assay. In brief, a freshly prepared XTT-PMS labeling
mixture (50 ml) was added to the cell culture. The absorbance was
measured at 450 nm with l correction at 650 nm. The cell
viability was expressed as DOD (OD450 -O D 650). The apoptosis
was determined by FACS analysis of propidium iodide (PI)-stained
cells. In brief, cells were trypsinized, washed with PBS and
resuspended in 200 ml PBS with 10 ml RNAase (10 mg ml/ml) and
incubated at 37uC for 30 min. After incubation, 50 ml PI solution
was added and cells were analyzed for apoptosis using a flow
cytometry (FACSCalibur, BD Biosciences, San Jose, CA).
Tumor spheroid assay
For spheroid forming assay, cells were plated in six-well ultralow
attachment plates (Corning Inc., Corning, NY) at a density of 1,000
cells/ml in DMEM supplemented with 1% N2 Supplement
(Invitrogen), 2% B27 Supplement (Invitrogen), 20 ng/ml human
platelet growth factor (Sigma-Aldrich), 100 ng/ml epidermal growth
factor (Invitrogen) and 1% antibiotic-antimycotic (Invitrogen) and
incubated at 37uC in a humidified atmosphere of 95% air and 5%
CO2. Cells were treated with GDC-0449 (10 mM) and spheroids were
collected by dissociation with Accutase (Innovative Cell Technologies,
Inc.) after 7 days. The CSCs obtained from dissociation were counted
by coulter counter using trypan blue dye.
Figure 6. Impact of SHH signaling pathway on the regulation of cell survival and antiproliferative effects of GDC-0449. (A), Knockout
of Gli1 shRNA and Gli2 shRNA in human pancreatic CSCs. Pancreatic CSCs were transduced with lentiviral particles expressing Scrambled, Gli1 shRNA,
Gli2 shRNA or Gli1 plus Gli2 shRNA (KO). (B), Pancreatic CSCs were treated with GDC-0449 (0, 1, 5 and 10 mM) for 72 h, and cell viability and apoptosis
was measured in scrambled and Gli1 plus Gli2 shRNA CSCs. Data represent mean 6 SD, n=4. @ or # significantly different from respective control
(P,0.05). (C), Scrambled and Gli1 plus Gli2 shRNA pancreatic CSCs were treated with GDC-0449 (0 and 10 mM) for 48 h, and lysates were extracted to
determine the expression of DR4, DR5, PDGFRa, Fas and Bcl-2 by Western blot analysis. b-Actin was used as the loading control. (D), Inhibition of
primary and secondary spheroids by GDC-0449. Pancreatic CSCs (scrambled, and Gli1 + Gli2 shRNA) were seeded in suspension and treated with
GDC-0449 (10 mM) for 7 days. At the end of incubation period, spheroids were collected, and dissociated with Accutase (Innovative Cell Technologies,
Inc.). For secondary spheroids, cells were reseeded and treated with GDC-0449 (10 mM) for additional 7 days. Cell viability was measured by trypan
blue assay. Data represent mean 6 SD. @ or # significantly different from respective controls, P,0.05.
doi:10.1371/journal.pone.0027306.g006
Inhibition of Pancreatic CSCs by GDC-0449
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27306Western blot analysis
Whole cell lysates were extracted from GDC-0449-treated cells
using RIPA lysis buffer containing 1 X protease inhibitor cocktail.
Protein concentrations were determined using the Bio-Rad Protein
Assay (Bio-Rad, Hercules, CA). Cell lysates containing 50 mgo f
protein were loaded and separated on 10% Tris-HCl gel. Proteins
from the gel were transferred on polyvinylidene difluoride mem-
branes and subsequently blocked in blocking buffer [5% nonfat dry
milk in 1 X Tris Buffer Saline (TBS)] and incubated overnight with
primary antibodies. Membranes were washed three times with TBS-
T for 10, 5, and 5 min each. After washing, membranes were
incubated with secondary antibodies conjugated with horseradish
peroxidase at 1:5,000 dilution in TBS for 1 h at room temperature.
Membranes were again washed three times in TBS-T and developed
using ECL Substrate. Protein bands were visualized on X-ray film
using an enhanced chemiluminescence system.
RNA isolation and mRNA expression analysis
Total RNA was isolated using the Qiagen RNeasy Mini Kit
according to the manufacturer’s protocol (Qiagen, Valencia, CA).
Briefly, RNA was isolated and reverse transcribed. cDNA
reactions were amplified with QPCR SYBR Green Mix. Primers
specific for each of the signaling molecules were designed using
NCBI/Primer-BLAST and used to generate the PCR products.
For the quantification of gene amplification, Real-time PCR was
performed using an ABI 7300 Sequence Detection System in the
presence of SYBR- Green. The following gene-specific primers
were used:
Smoothened (59-TCG CTA CCC TGC TGT TAT TC -39,5 9-
GAC GCA GGA CAG AGT CTC AT-39)
Patched1 (59-TGA CCT AGT CAG GCT GGA AG-39,5 9-
GAA GGA GAT TAT CCC CCT GA-39)
Patched2 (59-AGG AGC TGC ATT ACA CCA AG-39,5 9-
CCC AGG ACT TCC CAT AGA GT-39)
Gli1 (59-CTG GAT CGG ATA GGT GGT CT -39,5 9- CAG
AGG TTG GGA GGT AAG GA -39)
Gli2 (59-GCC CTT CCT GAA AAG AAG AC -39,5 9- CAT
TGG AGA AAC AGG ATT GG -39)
HK-GAPD (59-GAG TCA ACG GAT TTG GTC GT-39,5 9-
TTG ATT TTG GAG GGA TCT CG-39)
Figure 7. Schematic representation of the inhibition of SHH signaling and genes involved in the balance between cellular
proliferation and cell death. Activated Gli1 and Gli2, downstream of SHH-Patched-Smoothened, regulate targets of SHH signaling including Bcl-2,
PDGFRa, Fas, and DRs. GDC-0449 (targeting Smoothened) blocks the indirect functions of Gli activators, resulting in cell death.
doi:10.1371/journal.pone.0027306.g007
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by 40 cycles of 95uC for 15 s and 60uC for 1 min. HK-GAPD was
used as endogenous normalization control. All assays were
performed in triplicate and were calculated on the basis of DDCt
method. The n-fold change in mRNAs expression was determined
according to the method of 2
2DDCT.
Gli reporter assay (p-GreenFire1 Lenti-Reporter)
The cop-GFP and luciferase genes were cloned downstream of
Gli-response element, containing four Gli binding motifs (pGreen
Fire1-4xGli-mCMV-EF1-Neo; System Biosciences, Mountain
View, CA). For in vitro assays, stably transduced pancreatic CSCs
were plated at 5-10,000 cells per well in 12-well plates and treated
with 5 and 10 mM of GDC-0449. After incubation, CSCs were
analyzed for luciferase reporter activity (Promega Corp., Madison,
WI).
Immunocytochemistry
Pancreatic CSCs were grown on fibronectin-coated coverslips
(Beckton Dickinson, Bedford, MA) in the absence or presence of
10 mM of GDC-0449. Subsequently, cells were fixed with 4%
paraformaldehyde for 15 min, permeabilized with 0.1% Triton X-
100 in 1 X PBS, washed and blocked in 10% normal goat serum.
After extensive washing with PBS, cells were stained with Gli1 and
Gli2 primary antibodies (1:100) for 16 h at 4uC and washed with
PBS. Afterwards, cells were incubated with fluorescien-labeled
secondary antibody (1:200) along with DAPI (1 mg ml
21) for 1 h
at room temperature. Finally, coverslips were washed and
mounted using Vectashield (Vector Laboratories, Burlington,
CA). Isotype-specific negative controls were included with each
staining. Stained cells were mounted and visualized under a
fluorescent microscope.
Electrophorectic mobility shift assay (EMSA)
Gli probes were end-labeled with [c-
32P] dATP by incubating
oligodeoxyribonucleotide strands with 5 x reaction buffer and
10 U T4 polynucleotide kinase for 1 h at 37uC. Then labeled
oligonucleotides were allowed to anneal at room temperature for
10 min and 20 mg protein from each sample treated with GDC-
0449 (0, 1, 5 and 10 mM) was used in 25 ml binding reactions,
which consisted of 1 mg poly dI-dC, in 5 X binding buffer
(50 mM Tris HCl; pH 8.0, 0.75 M KCl, 2.5 mM EDTA, 0.5%
Triton-X 100, 62.5% glycerol (v/v) and 1 mM DTT). To
determine specificity of DNA binding, samples were incubated
with or without 20 ng of unlabeled competitor DNA for 10 min at
room temperature. Then 0.1 ng of labeled probe of Gli was added
and samples were further incubated for 20 min at room
temperature. Samples were separated on a 5% non-denaturing
polyacrylamide gel in 0.5% TBE and visualized by autoradiog-
raphy.
Statistical analysis
The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one or two
way ANOVA using PRISM statistical analysis software (GrafPad
Software, Inc., San Diego, CA). Significant differences among
groups were calculated at P,0.05.
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